KYNTRA BIO, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
KYNTRA BIO, INC. (KYNB) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$47.92 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-16
- KYNTRA BIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$47.92M.
- KYNTRA BIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$142.82M.
- KYNTRA BIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$324.58M.
- KYNTRA BIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$307.06M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$47.92M 10-K · filed 2026-03-16 | |
| 2024-12-31 | -$142.82M 10-K · filed 2026-03-16 | |
| 2023-12-31 | -$324.58M 10-K · filed 2025-03-17 | -$328.48M 10-K · filed 2024-02-26 |
| 2022-12-31 | -$307.06M 10-K · filed 2024-02-26 | |
| 2021-12-31 | -$268.50M 10-K · filed 2024-02-26 | |
| 2020-12-31 | -$195.62M 10-K · filed 2023-02-27 | |
| 2019-12-31 | $2.54M 10-K/A · filed 2022-03-04 | |
| 2018-12-31 | -$38.47M 10-K · filed 2021-03-01 | |
| 2017-12-31 | -$80.73M 10-K · filed 2020-03-02 | -$101.23M 10-K · filed 2018-02-27 |
| 2016-12-31 | -$25.34M 10-K · filed 2019-02-27 | -$38.16M 10-K · filed 2017-03-01 |
| 2015-12-31 | -$66.41M 10-K · filed 2018-02-27 | |
| 2014-12-31 | -$47.00M 10-K · filed 2017-03-01 | |
| 2013-12-31 | -$3.11M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |